entertainment -WSS

entertainment

author：focus 2025-10-02 22:27:30 - browse：481

Courtesy Guardant Health

An independent panel of advisers to the Food and Drug Administration recommended the agency approve Guardant Health’s blood-based colon cancer detection test. If the agency follows the recommendation, it will clear an early hurdle for the test’s broader adoption.

The expert panel spent hours listening to presentations from Guardant, the FDA, and members of the public before voting on the screening test, called Shield. The panel’s nine voting members then voted on whether the test was safe, effective, and whether its benefits outweigh its risks, with eight, six, and seven panelists endorsing those views, respectively.

FDA approval is a requirement for winning coverage from the Centers for Medicare and Medicaid Services, which could be the difference between Guardant’s test becoming widespread — or irrelevant. In 2021, CMS denied coverage for Epi proColon, a different blood-based colon cancer test approved by the FDA. Soon after, the test’s maker, Epigenomics, announced that it would stop actively marketing the test, and last year the company announced a restructuring that included layoffs.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： EU fines Illumina $475 million over Grail acquisition

WSS

After half a century, Israel moves to evict squatter from his cave home on the beach

White House pharmacy plagued with problems, investigation finds

New clues to why women have higher risk of autoimmune disorders

Companies helping big Covid

Medicare Advantage insurers face 0.2% cut to 2025 payments

Russia's threat to pull out of Ukraine grain deal raises fears about global food security

Wikipedia

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Virginia high school admissions case could be legal follow

Tommy Tuberville reverses his claim that white nationalists are unfairly labeled racist

DIEP, the 'gold standard' of breast reconstruction, is under threat

Tornado touches down near Chicago's O'Hare airport amid extreme weather nationwide

Tori Bowie and the unacceptable rates of Black maternal death

Why you shouldn’t ask, “What country has the best health care?”

Apple is now the first public company to be valued at $3 trillion

10 reasons why health care startups fail

Heart attack and stroke risk calculators need revising

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

focus

Antibody drugs appear effective. Now can we make enough of them?

The Affordable Care Act has saved billions in health care costs

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

Merck CEO won’t testify in Senate, citing no expertise in drug prices

Reconstructing family trees of blood cells may help predict disease

White House pharmacy plagued with problems, investigation finds

entertainment

hotspot

entertainment

knowledge